Drug Trial Radar · NCT02820025
The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence
Last checked: Nov 20, 2026Latest source record: Jan 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Actual
Start
Oct 2015
Primary completion
Apr 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- General Hospital of Ningxia Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 30, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current study is designed to investigate the difference of plasma orexin A levels between doxapram group and controlled group at emergence time from sevoflurane-remifentanil anesthesia who will undergo elective lumbar surgery.
Conditions
- Anesthesia
Interventions
doxapramDrug
salineOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- orexin A concentrationsTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anesthesiology department of General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.